Complement activation: The missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies

Thrombosis and Haemostasis

Volumn 93, Issue 3, 2005, Pages 443-452

  Ruiz Torres, Maria Piedad ^a,b   Casiraghi, Federica ^a   Galbusera, Miriam ^a   Macconi, Daniela ^a   Gastoldi, Sara ^a   Todeschini, Marta ^a   Porrati, Francesca ^a   Belotti, Daniela ^c   Pogliani, Enrico Maria ^c   Noris, Marina ^a   Remuzzi, Giuseppe ^a,d  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c SAN GERARDO HOSPITAL   (Italy)

^d OSPEDALI RIUNITI   (Italy)

Author keywords

ADAMTS 13; Complement; Neutrophils; Reactive oxygen species; Thrombotic microangiopathy

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT MEMBRANE ATTACK COMPLEX; GELATINASE B; OXIDIZING AGENT; PADGEM PROTEIN; REACTIVE OXYGEN METABOLITE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; BLOOD VESSEL INJURY; CELL ISOLATION; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIUM CELL; ENDOTHELIUM LESION; ENZYME DEFICIENCY; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULAR RESISTANCE;

ADAM PROTEINS; CELL LINE; COMPLEMENT ACTIVATION; ENDOTHELIUM, VASCULAR; HEMOLYTIC-UREMIC SYNDROME; HUMANS; NEUTROPHIL ACTIVATION; OXIDANTS; PEPTIDE HYDROLASES; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REACTIVE OXYGEN SPECIES;

EID: 20144365269     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-07-0450     Document Type: Article

References (37)

1. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001; 60: 831-46.
2. Caprioli J, Bettinaglio P, Zipfel PF, et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 2000; 12: 297-307.
3. Noris M, Brioschi S, Caprioli J, et al. for the International Registry of Recurrent and Familial HUS/TTP. Familial haemolytic uraemic syndrome and MCP mutation. Lancet 2003; 362: 1542-7.
4. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 475-6.
5. Kokame K, Matsumoto M, Soejima K, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA. 2002; 99: 11902-7.
6. Remuzzi G, Galbusera M, Noris M, et al. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 2002; 100: 778-85.
7. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84.
8. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-94.
9. Forsyrth KD, Simpson AC, Fitzpatrick MM, et al. Neuthrophil-mediated endothelial injury in haemolytic uraemic syndrome. Lancet 1989; 2: 411-4.
10. Noris M, Ruggenenti P, Todeschini M, et al. Increased nitric oxide formation in recurrent thrombotic microangiopathies: a possible mediator of microvascular injury. Am J Kidney Dis 1996; 27: 790-6.
11. Stoncek DF, Vercellotti GM, Ammerschmidt DE, et al. Characterization of multiple quinine-dependent antibodies in a patient with episodic hemolytic uremic syndrome and immune agranulocytosis. Blood 1992; 80: 241-8.
12. Mitra D, Jaffe EA, Weksler B, et al. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood 1997; 89: 1224-34.
13. Alvarez-Larràn A, Petriz J, Martìnez A, et al. Plasma from patients with thrombotic thrombocytopenic purpura induces activaction of human monocytes and polymorphonuclear neutrophils. Br J Haematol 2003; 120: 129-34.
14. Valant PA, Jy W, Horstman LL, et al. Thrombotic thrombocytopenic purpura plasma enhances platelet-leukocyte interaction in vitro. Br J Haematol 1998; 100: 24-32.
15. Eiserich JP, Haristova M, Cross CE, et al. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 1998; 301: 393-7.
16. Morigi M, Galbusera M, Binda E, et al. Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood 2001; 98: 1828-35.
17. Ribeiro MJA, Philiphs DJ, Benson JM, et al. Hemostatic properties of the SV-40 transfected human microvascular endothelial cell line (HMEC-1). A representative in vitro model for microvascular endothelium. Thromb Res 1995; 79: 153-61.
18. Situnayake RD, Crump BJ, Thurman DI, et al. Further evidence of lipid peroxidation in post-enteropathic haemolytic-uraemic syndrome. Pediatr Nephrol 1991; 5: 387-92.
19. Milford DV, Staten J, McGrecor I, et al. Prognostic markers in diarrhea-associated haemolytic-uraemic syndrome: intial neuthrophil count, human neuthrophil elastase and von Willebrand factor antigen. Nephrol Dial Transplant 1991; 6: 232-7.
20. Fitzpatrick MM, Shah V, Trompeter RS, et al. Interleukin-8 and polymorphoneuthrophil leukocyte activation in hemolytic uremic syndrome of childhood. Kidney Int 1992; 42: 951-6.
21. Kilgore KS, Ward PA, Warren JS. Neuthrophil adhesion to human endothelial cells is induced by the membrane attack complex: the roles of P-selectin and platelet activating factor. Inflammation 1998; 22: 583-98.
22. Foreman KE, Vaporciyan AA, Bonish BK, et al. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 1994; 94: 1147-55.
23. McEver RP. Adhesive interaction of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 2001; 86: 746-56.
24. van Epps DE, Chenoweth DE. Analysis of the binding of fluorescent C5a and C3a to human peripheral blood leukocytes. J Immunol 1984; 132: 2862-7.
25. Elsner J, Opperman M, Czech W, et al. C3a activates the respiratory burst in human polymorphonuclear neuthrophilic leukocytes via pertussis toxin sensitive G-protein. Blood 1994; 83: 3324-31.
26. Hardy MM, Flickinger AG, Riley DP, et al. Superoxide dismutase mimetics inhibit neuthrophil-mediated human aortic endothelial cell injury in vitro. J Biol Chem 1994; 269: 18535-40.
27. Noris M, Ruggenenti P, Perna A, et al. Hypocomplementemia discoloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian registry of familial and recurrent hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. J Am Soc Nephrol 1999; 10: 281-93.
28. Wright JF, Wang H, Horsnstein A, et al. Characterization of platelet glycoproteins and platelet/endothelial cell antibodies in patients with thrombotic thrombocytopenic purpura. Br J Haematol 1999; 107: 546-55.
29. Weisenburger DR, O'Connor ML, Hart MN. Thrombotic thrombocytopenic purpura with C3 vascular deposits: report of a case. Am J Clin Pathol 1977; 67: 61-3.
30. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 4033-9.
31. Polley MJ, Nachman R. The human complement system in thrombin-mediated platelet function. J Exp Med 1978; 147: 1713-26.
32. Cheung AK, Faeizi-Jenkin B, Leypoldt JK. Effect of thrombosis on complement activation and neuthrophil degranulation during in vitro hemodialysis. J Am Soc Nephrol 1994; 5: 110-5.
33. Ekdahl KN, Nilsson B. Phosphorilation of plasma proteins with emphasis on complement component C3. Mol Immunol 1999; 36: 233-9.
34. Ekdahl KN, Nilsson B. Phosphorilation of complement component C3 and C3 fragments by a human platelet protein kinase. Inhibition of factor I-medited cleavage of C3b. J Immunol 1995; 154: 6502-10.
35. Ekdahl KN, Nilsson B. Alteration in C3 activation and binding caused by phosphorilation by a casein kinase released from activated human platelets. J Immunol 1999; 162: 7426-33.
36. Ekdahl KN, Ronnblom L, Sturfelt G, et al. Increased phosphate content in complement component C3, fibrinogen, vitronectin, and other plasma proteins in systemic lupus erythematosus: covariation with platelet activation and possible role association with thrombosis. Arthritis Rheum 1997; 40: 2178-86.
37. Smith RA. Targeting anticomplement agents. Biochem Soc Trans 2001; 30: 1037-41.